Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Monopar Therapeutics LLC

Developing orphan oncology drugs

This article was originally published in Start Up

Executive Summary

Monopar Therapeutics LLC is focusing on developing treatments for hard-to-treat cancer subtypes. Its lead program, huATN-658, is a humanized monoclonal antibody that targets the urokinase plasminogen activator receptor (uPAR). A protein receptor, uPAR is found on certain cancer cells, but it has little to no expression on healthy tissue; it is linked with tumor cell survival, its expression increases in high-grade and metastatic disease and it is correlated with a worse prognosis in several cancers.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts